Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anavex Life Sciences Corp. - Common Stock (NQ:AVXL)

8.965 -0.065 (-0.72%)
Streaming Delayed Price Updated: 3:47 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anavex Life Sciences Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
34 Stocks Moving In Tuesday's Mid-Day Session
Gainers Biofrontera Inc. (NASDAQ: BFRI) shares climbed 30.7% to $4.4095 after the company provided an update on patient recruitment for the Phase III study for the treatment of... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 25.6% to $1.42 during Tuesday's regular session. Trading volume for Windtree Therapeutics's stock is 652.4K... 
Via Benzinga
Mid-Day Market Update: Pitney Bowes Drops After Q4 Earnings; Biofrontera Shares Climb
US stocks traded mostly flat on Tuesday after recording sharp gains in the previous session. Wall Street closed the volatile January month with steep losses. 
Via Benzinga
Anavex Life Sciences Says Rett Syndrome Trial Meets Primary & Secondary Goals
Anavex Life Sciences Corp (NASDAQ: AVXL) reported topline data from the Phase 3 AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome. 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Lower Following Monday's Rally; UPS Earnings Top Views
US stocks started the first trading day of new month on a cautious note after recording gains on Monday. Wall Street closed the volatile January month with steep losses. 
Via Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Molecular Partners (NASDAQ:MOLN) shares moved upwards by 11.9% to $31.66 during Friday's pre-market session. The market value of their outstanding shares is at... 
Via Benzinga
Anavex Life's Neurodegenerative Disease Candidate Meets Primary Endpoint In Early-Stage Study
Anavex Life Sciences Corp (NASDAQ: AVXL) announced topline results from its Phase 1 trial of ANAVEX3-71 in development for neurodegenerative diseases, including... 
Via Benzinga
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts, and COVID-19 treatment and vaccine developments dictating sentiment. Here are the key... 
Via Talk Markets
The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year
Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares in... 
Via Benzinga
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By... 
Via Benzinga
Topics Intellectual Property
Earnings Scheduled For November 24, 2021
Companies Reporting Before The Bell • Centogene (NASDAQ:CNTG) is likely to report quarterly loss at $0.55 per share on revenue of $31.75 million. • Anavex Life... 
Via Benzinga
Earnings Outlook For Anavex Life Sciences
Anavex Life Sciences (NASDAQ:AVXL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement.... 
Via Benzinga
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
Via Talk Markets
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's pre-market session. The company's market cap stands at $27.1... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ: 
Via Benzinga
Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease. 
Via The Motley Fool
Anavex Life Sciences (AVXL) Q3 2021 Earnings Call Transcript
AVXL earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS... 
Via Benzinga
70 Biggest Movers From Yesterday
Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently reported closing of $12.5 million private... 
Via Benzinga
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers NanoVibronix (NASDAQ:NAOV) share... 
Via Benzinga
Anavex Life's Stock Declines Despite Data Shows Alzheimer's Candidate Prevent Abeta-Induced Cognitive Decline In Animal Study
Anavex Life Sciences Corp (NASDAQ: AVXL) has reported new preclinical data for its Alzheimer's candidate, ANAVEX2-73 (blarcamesine). Pre-treatment with... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Cocrystal Pharma (NASDAQ:COCP) stock moved upwards by 30.9% to $1.44 during Thursday's pre-market session. The company's market cap stands at $140.3... 
Via Benzinga
21 Stocks Moving in Monday's Pre-Market Session
Gainers Creatd Inc (NASDAQ: CRTD) shares rose 33.9% to $4.27 in pre-market trading after dropping around 9% on Friday. Oxbridge Re Holdings Ltd (NASDAQ: OXBR) shares rose 13.2%... 
Via Benzinga
Biogen Stock Drags On Alzheimer's Players As FDA Requests Review Of Aduhelm Approval
Biogen stock tumbled Friday after the FDA requested an independent review of the process that led to its recent Alzheimer's approval. 
Via Investor's Business Daily
Cramer Shares His Thoughts On Anavex Life Sciences, Upstart And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he is intrigued about Anavex Life Sciences Corp (NASDAQ: AVXL) because Biogen Inc (NASDAQ: BIIB) data doesn... 
Via Benzinga
Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021
Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) advancing about 8% year-to-date ... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.